SML0654
Entacapone
≥98% (HPLC)
Synonym(s):
2-Cyano-N,N-diethyl-3-(3,4-dihydroxy-5-nitrophenyl)propenamide
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
Quality Level
Assay
≥98% (HPLC)
form
powder
color
white to light brown
solubility
DMSO: 20 mg/mL, clear
storage temp.
room temp
InChI
1S/C14H15N3O5/c1-3-16(4-2)14(20)10(8-15)5-9-6-11(17(21)22)13(19)12(18)7-9/h5-7,18-19H,3-4H2,1-2H3/b10-5+
InChI key
JRURYQJSLYLRLN-BJMVGYQFSA-N
Looking for similar products? Visit Product Comparison Guide
Application
Entacapone has been used in high-performance bioaffinity chromatography.
Biochem/physiol Actions
Entacapone acts predominantly in the intestine. It increases the bioavailability of levodopa. Levodopa is known to be associated with many complications such as motor fluctuations. COMT inhibitors have been used to overcome these adverse effects of levodopa by reducing its metabolism. Entacapone exhibits its inhibition action on COMT in the peripheral nervous system.
Entacapone is a catechol-O-methyl transferase (COMT) inhibitor. Used in treatment of Parkinson′s disease, entacapone is administered with L-DOPA to inihibit COMT from converting L-DOPA into a compound that cannot cross the blood brain barrier.
Features and Benefits
This compound is featured on the Dopamine and Norepinephrine Metabolism page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Principles of Treatment in Parkinson's Disease, 133-133 (2005)
Entacapone in the treatment of Parkinson's disease
Lancet Neurology, 4(6), 366-370 (2005)
Behavioural brain research, 280, 92-100 (2014-12-02)
Dopamine encodes reward and its prediction in reinforcement learning. Catechol-O-methyltransferase (COMT) activity in the medial prefrontal cortex (mPFC) has been shown to influence cognitive abilities by modifying dopamine clearance. Nevertheless, it is unknown how COMT in the mPFC influences operant
Expanding LogP: Present possibilities
Nuclear Medicine and Biology, 58(6), 20-32 (2018)
Journal of neuroimmunology, 276(1-2), 135-141 (2014-09-23)
Reduced levels of noradrenaline (NA) in CNS of multiple sclerosis patients could be due to metabolism by catechol-O-methyltransferase (COMT). In mice immunized with myelin oligodendrocyte glycoprotein peptide, the BBB-permeable COMT inhibitor dinitrocatechol (DNC) reduced clinical signs, while entacapone, a non-BBB-permeable
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service